Chertkow H., Bergman H., Schipper H. M., Gauthier S., Bouchard R., Fontaine S., Clarfield A. M. (2001). Assessment of suspected dementia, Can J Neurol Sci, 28 Suppl 1, S28-41.

Feldman H., Gauthier S., Hecker J., Vellas B., Subbiah P., Whalen E. (2001). A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease, Neurology, 57(4), 613-20.

Feldman H., Sauter A., Donald A., Gelinas I., Gauthier S., Torfs K., Parys W., Mehnert A. (2001). The disability assessment for dementia scale: a 12-month study of functional ability in mild to moderate severity Alzheimer disease, Alzheimer Dis Assoc Disord, 15(2), 89-95.

Gauthier S. (2001). Alzheimer's disease: current and future therapeutic perspectives, Prog Neuropsychopharmacol Biol Psychiatry, 25(1), 73-89.

Gauthier S. (2001). Cholinergic adverse effects of cholinesterase inhibitors in Alzheimer's disease: epidemiology and management, Drugs Aging, 18(11), 853-62.

Gauthier S. (2001). Muscarinic agonists . In Gauthier S. & Cummings J. L. (Eds.) , Alzheimer's Disease and Related Disorders Annual (pp. 85-96). Martin Dunitz Ltd..

Gauthier S., Ferris S. (2001). Outcome measures for probable vascular dementia and Alzheimer's disease with cerebrovascular disease, Int J Clin Pract Suppl(120), 29-39.

Gauthier S., Gauthier S., Dupin F., Panisset M. (2001). Comment déterminer l'aptitude du mandant? . In Formation permanente du Barreau du Québec, (Ed.) , Les mandats en cas d'inaptitude: une panacée? (pp. 71-82). Les Éditions Yvon Blais Inc..

Gauthier S., Gauthier S., Dupin F., Panisset M. (2001). Comment déterminer l'aptitude du mandant? . In Formation permanente du Barreau du Québec, (Ed.) , Les mandats en cas d'inaptitude: une panacée? (pp. 71-82). Les Éditions Yvon Blais Inc..

Kibar Z., Underhill D. A., Canonne-Hergaux F., Gauthier S., Justice M. J., Gros P. (2001). Identification of a new chemically induced allele (Lp(m1Jus)) at the loop-tail locus: morphology, histology, and genetic mapping, Genomics, 72(3), 331-7.

Law A., Gauthier S., Quirion R. (2001). Say NO to Alzheimer's disease: the putative links between nitric oxide and dementia of the Alzheimer's type, Brain Res Brain Res Rev, 35(1), 73-96.

Law A., Gauthier S., Quirion R. (2001). Neuroprotective and neurorescuing effects of isoform-specific nitric oxide synthase inhibitors, nitric oxide scavenger, and antioxidant against beta-amyloid toxicity, Br J Pharmacol, 133(7), 1114-24.

Patterson C., Gauthier S. (2001). Canadian consensus conference on dementia: two years later, Can J Neurol Sci, 28 Suppl 1, S1-2.

Patterson C., Gauthier S., Bergman H., Cohen C., Feightner J. W., Feldman H., Grek A., Hogan D. B. (2001). The recognition, assessment and management of dementing disorders: conclusions from the Canadian Consensus Conference on Dementia, Can J Neurol Sci, 28 Suppl 1, S3-16.

Rockwood K., Black S., Gauthier S., Feldman H., Wentzell C. (2001). Clinical and neuroimaging findings in mixed dementia, Res Pract Alzheimer Dis, 5, 115-122.

Tomossy G. F., Weisstub D. N., Gauthier S. (2001). Regulating ethical research involving cognitively impaired elderly subjects. Canada as a case study . In Weisstub D. N., Thomasma D. C., Gauthier S., Tomossy G. F. & Weisstub D. N. (Eds.) , Aging: Decisions at the End of Life (pp. 227-254). Kluwer Academic Publishers..

Wentzel C., Rockwood K., MacKnight C., Hachinski V., Hogan D. B., Feldman H., Ostbye T., Wolfson C., Gauthier S., Verreault R., McDowell I. (2001). Progression of impairment in patients with vascular cognitive impairment without dementia, Neurology, 57(4), 714-6.

Winblad B., Brodaty H., Gauthier S., Morris J. C., Orgogozo J. M., Rockwood K., Schneider L., Takeda M., Tariot P., Wilkinson D. (2001). Pharmacotherapy of Alzheimer's disease: is there a need to redefine treatment success?, Int J Geriatr Psychiatry, 16(7), 653-66.